Assure (IONM) Competitors

Assure (NASDAQ:IONM) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Does the MarketBeat Community believe in IONM or BIOL?

BIOLASE received 289 more outperform votes than Assure when rated by MarketBeat users. Likewise, 51.05% of users gave BIOLASE an outperform vote while only 27.27% of users gave Assure an outperform vote.

Company	Underperform	Outperform
Assure	Outperform Votes 3 27.27%	Underperform Votes 8 72.73%
BIOLASE	Outperform Votes 292 51.05%	Underperform Votes 280 48.95%

Which has more risk and volatility, IONM or BIOL?

Assure has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Which has preferable earnings & valuation, IONM or BIOL?

BIOLASE has higher revenue and earnings than Assure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assure	$149K	1.01	-$26.08M	N/A	N/A
BIOLASE	$48.83M	0.01	-$20.63M	-$14.94	0.00

Does the media prefer IONM or BIOL?

In the previous week, Assure's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Company	Overall Sentiment
Assure	Neutral
BIOLASE	Neutral

Is IONM or BIOL more profitable?

BIOLASE has a net margin of -41.65% compared to Assure's net margin of -25,178.32%. Assure's return on equity of 0.00% beat BIOLASE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assure	-25,178.32%	N/A	-249.78%
BIOLASE	-41.65%	-1,782.73%	-55.31%

Do insiders & institutionals have more ownership in IONM or BIOL?

3.3% of Assure shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 3.8% of Assure shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts rate IONM or BIOL?

BIOLASE has a consensus target price of $1.20, indicating a potential upside of 9,577.42%. Given BIOLASE's stronger consensus rating and higher probable upside, analysts plainly believe BIOLASE is more favorable than Assure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

BIOLASE beats Assure on 10 of the 14 factors compared between the two stocks.